Pediatric adverse event review
FDA's Pediatric Advisory Committee will meet March 25 to discuss adverse event reports for several drugs used in pediatric patients, as mandated by the Best Pharmaceuticals for Children Act. Drugs discussed will include: AstraZeneca's Toprol XL, Baxter's Brevibloc and Suprane, Novartis' Lotensin, GlaxoSmithKline's Coreg, Salix's Colazal, Sanofi-Aventis' Eloxatin and Pfizer's Celebrex...
You may also be interested in...
While endocrine-disrupting evidence was inconclusive, the Scientific Committee on Consumer Safety recommends more conservative limits on use of homosalate, octocrylene and benzophenone-3 in cosmetic products compared with current requirements under the European Cosmetics Product Regulation.
The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.
Move was meant to preempt others’ efforts to secure the next six months of Regeneron’s COVID-19 antibody therapeutic.